BioTelemetry to pay $44.8M over India testing false claims
By 
Adrianne Appel2022-12-21T20:21:00
Medical technology company BioTelemetry and its heart rate monitoring subsidiary CardioNet agreed to pay more than $44.8 million to settle allegations they violated U.S. federal health laws by improperly billing Medicare and other federal programs for heart monitoring and cardiac test analyses performed by a company in India.
Federal law requires services for patients of federal health programs, like Medicare, be provided within the United States to be reimbursed.
The trouble began for BioTelemetry in 2013, when it contracted with a group in India to conduct Holter-associated monitoring and interpret the results. The Holter heart monitor is designed to detect faulty and dangerous heart rhythms related to heart attacks and poor heart function.
Related articles
-
News BriefPhilips unit settles DOJ false claims case for $14.7M
Wireless medical technology company BioTelemetry and its subsidiary LifeWatch Services agreed to pay more than $14.7 million as part of a settlement with the Department of Justice regarding alleged false claims submitted to federal healthcare programs.
-
News Brief
Spacelabs Healthcare to pay $2.5M over VA contract false claims
Spacelabs Healthcare agreed to pay $2.5 million as part of a settlement with the Department of Justice resolving allegations it overcharged the U.S. Department of Veterans Affairs for medical devices.
-
News BriefFalse Claims Act settlements net lower return in FY2022
Penalties assessed for violations of the False Claims Act topped $2.2 billion during fiscal year 2022, less than half the mark the Department of Justice reached the previous year.
More from Regulatory Enforcement
-
News BriefJudge reinstates fired CPSC commissioners in latest battle over government cuts
In May, three commissioners for the Consumer Product Safety Commission were abruptly fired by President Donald Trump and sued for their jobs shortly after. A federal judge has ruled that the commissioners should be reinstated, although it’s unclear whether that ruling may itself be reversed.
-
PremiumUK’s Failure to Prevent Fraud law may expose firms to unlimited fines and prosecution, says Moody’s compliance risk expert
Fraud now accounts for around 40% of all crime in the U.K., posing a major problem for banks and consumers. Ted Datta, head of industry practice for financial crime compliance at Moody’s, warns that the risk is growing fast.
-
ArticleCrypto firms brace for tighter UK oversight as FCA plots integration with financial markets
Trying to put rules in place to oversee an industry that has grown largely outside of regulation is not without serious challenges. But the UK’s Financial Conduct Authority’s (FCA) latest consultation aims to attract industry views about how some key aspects of crypto trading should be regulated ahead of planned ...